Trial Profile
Mifepristone Treatment for Breast Cancer Patients Expressing Levels of Progesterone Receptor Isoform A (PRA) Higher Than Those of Isoform B (PRB): Neoadjuvant Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2022
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms MIPRA
- 12 Oct 2022 Results assessing the beneficial effects of mifepristone treatment in breast cancer patients, published in the Clinical Cancer Research.
- 29 Jul 2020 Status changed from active, no longer recruiting to completed.
- 02 Nov 2019 Status changed from recruiting to active, no longer recruiting.